HopeStage
Back to all studies
CompletedNCT03053362

Tracking Cognitive Changes With THINC-it During Vortioxetine Treatment

About this titleRead the official source — NCT03053362
Medication studyAges 18–65CanadaDepression
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 24, 2017
Recruitment status
Completed
Enrollment listed in the registry
158
Sponsor
Brain and Cognition Discovery Foundation
Sponsor type
Non-profit organization
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT03053362
Official title
Show the full official title

An Open-Label Clinical Trial Evaluating Sensitivity to Change in Cognition Using the THINC-it Following Treatment With Vortioxetine in Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Brain and Cognition Discovery Foundation.

Did this study involve medication?

Yes. The study involved medication, including Vortioxetine.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies